Draft:Mark Connors (physician)
| Submission declined on 10 June 2024 by Liance (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This submission does not appear to be written in the formal tone expected of an encyclopedia article. Entries should be written from a neutral point of view, and should refer to a range of independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid peacock terms that promote the subject.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 16 May 2024 by HitroMilanese (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. Declined by HitroMilanese 28 days ago. | |
| Submission declined on 16 May 2024 by Umakant Bhalerao (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. Declined by Umakant Bhalerao 28 days ago. | |
Comment: Needs to be significantly rewritten to remove MOS:PUFFERY wording. Only primary sources are cited at time of review. ~Liancetalk 21:31, 10 June 2024 (UTC)
- Comment: The title of this draft either has been disambiguated or will require disambiguation if accepted.If this draft has been disambiguated (renamed), submitters and reviewers are asked to consider whether the current title is the best possible disambiguation, and, if necessary, move (rename) this draft.If this draft is accepted, a hatnote will need to be added to the primary page to refer to this page. If there is already a hatnote on the primary page, please review whether a disambiguation page is in order instead. Please do not edit the primary page unless you are accepting this draft.The primary page is Mark Connors. Robert McClenon (talk) 19:20, 9 June 2024 (UTC)
- Comment: Additional references in independent and reliable sources are needed to demonstrate notability. Hitro talk 13:22, 16 May 2024 (UTC)
Mark Connors | |
|---|---|
 | |
| Alma mater | Temple University (BA) Temple University (MD) |
| Known for | Research on Long-term nonprogressors |
| Scientific career | |
| Fields | Immunology |
Mark Connors, M.D., is a prominent researcher at the National Institutes of Health (NIH) specializing in HIV/AIDS. He serves as the Chief of the HIV-Specific Immunity Section at the National Institute of Allergy and Infectious Diseases (NIAID), where he oversees efforts to understand and enhance the immune response to HIV and other viruses. His research focuses on identifying effective immune responses to viruses, which are crucial for developing vaccines and immunotherapies.[1]
Career and Research[edit]
Dr. Connors received his medical degree from Temple University, followed by pediatric training at Tufts Medical Center, and infectious diseases training at NIAID and the Children's Hospital of Philadelphia. He has been with the NIH since 1989, initially studying the immune response to respiratory viruses before shifting his focus to HIV in 1994. His career highlights include pioneering studies on the immunologic control of HIV, particularly in Long-term nonprogressor or "elite controllers" who can control HIV without antiretroviral therapy. The study of this group of patients has laid the foundation for our understanding of an effective immune response to HIV and provided insights into potential strategies for HIV treatment and prevention.[1]
In addition to his work on the cellular immune response to HIV, he has made numerous contributions to our understanding of the antibody response. These include identifying patients with broad antibody responses to HIV, and from these patients isolating broad and potent monoclonal antibodies that define sites of vulnerability on HIV envelope protein. These antibodies include isolation of broad and potent antibodies 10E8, 35O22, and N6, among others a potent antibody that can neutralize nearly all HIV strains.[2] This discovery has significant implications for the development of HIV treatments and vaccines, as it targets a crucial part of the virus that attaches to immune cells, making it a promising candidate for therapeutic use.
Dr. Connors' work has not only contributed to our understanding of HIV but also has implications for broader immunological research and public health. His publications and contributions to the scientific community are widely recognized and continue to influence the field of HIV research significantly.
References[edit]
- ^ a b "Mark Connors, M.D."
- ^ {{Cite web |title=NIH Scientists Identify Potent Antibody that Neutralizes Nearly All HIV Strains |date=18 November 2016 <ref>
This article incorporates public domain material from websites or documents of the National Institutes of Health.